ACM
NAVB

Allred Capital Management’s Navidea Biopharmaceuticals Inc. NAVB Stock Holding History

Allred Capital Management’s Portfolio NAVB Stock Details NAVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-466,688
Closed -$41.9K – 169
2023
Q3 		$41.9K Buy
466,688
+172,850
+59% +$16K 0.02% 151
2023
Q2 		$27K Buy
293,838
+129,100
+78% +$20.6K 0.01% 159
2023
Q1 		$42.8K Buy
164,738
+54,300
+49% +$15.9K 0.02% 156
2022
Q4 		$23.2K Buy
110,438
+63,200
+134% +$15.8K 0.01% 152
2022
Q3 		$11K Buy
47,238
+10,400
+28% +$4.85K 0.01% 150
2022
Q2 		$26K Sell
36,838
-14,784
-29% -$12.6K 0.02% 155
2022
Q1 		$40K Sell
51,622
-1,616
-3% -$1.48K 0.02% 168
2021
Q4 		$53K Sell
53,238
-11,750
-18% -$16.5K 0.03% 184
2021
Q3 		$114K Sell
64,988
-8,800
-12% -$14.8K 0.06% 173
2021
Q2 		$135K Buy
73,788
+9,785
+15% +$17.3K 0.07% 179
2021
Q1 		$129K Buy
64,003
+11,077
+21% +$25.9K 0.06% 226
2020
Q4 		$113K Sell
52,926
-12,377
-19% -$29.2K 0.06% 168
2020
Q3 		$176K Sell
65,303
-3,163
-5% -$11.3K 0.11% 157
2020
Q2 		$269K Buy
68,466
+47,938
+234% +$91.7K 0.17% 124
2020
Q1 		$15K Sell
20,528
-3,600
-15% -$3.97K 0.01% 136
2019
Q4 		$30.4K Buy
24,128
+12,810
+113% +$11.1K 0.02% 404
2019
Q3 		$8K Sell
11,318
-8,100
-42% -$4.98K ﹤0.01% 163
2019
Q2 		$11K Buy
19,418
+6,784
+54% +$13.2K 0.01% 178
2019
Q1 		$35K Buy
12,634
+2,185
+21% +$6.45K 0.02% 188
2018
Q4 		$21K Buy
+10,449
New +$43.1K 0.01% 173

Other funds holding NAVB

BBA
Baader Bank Aktiengesellschaft Unterschleissheim, Germany $1.28B AUM 38.1% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $5.56B AUM 17.89% 1-Year Est. Return
ASN
Advisory Services Network Atlanta, Georgia $7.52B AUM 29.01% 1-Year Est. Return
BCMLT
Beacon Capital Management LLC (Tennessee) Franklin, Tennessee $567M AUM 16.01% 1-Year Est. Return

Allred Capital Management's NAVB Position: Q4 2023 in Review

Allred Capital Management sold out of Navidea Biopharmaceuticals Inc. (NAVB) in Q4 2023, closing a stake of 466,688 shares — an estimated $41.9K sold.

Allred Capital Management first reported a position in NAVB in Q4 2018 and held it in 20 quarters. The position peaked at $269K in Q2 2020. 4 funds tracked by Wall St. Rank hold NAVB as of Q4 2023.

  • Allred Capital Management reported no remaining Navidea Biopharmaceuticals Inc. position as of Q4 2023 after selling out during the quarter.
  • Allred Capital Management sold 466,688 Navidea Biopharmaceuticals Inc. shares in Q4 2023, an estimated $41.9K.
  • Allred Capital Management first reported a position in Navidea Biopharmaceuticals Inc. in Q4 2018 and held it in 20 quarters.
  • Allred Capital Management's Navidea Biopharmaceuticals Inc. position peaked at $269K in Q2 2020.
  • 4 funds tracked by Wall St. Rank held Navidea Biopharmaceuticals Inc. as of Q4 2023.

Based on Allred Capital Management's 13F filing for Q4 2023, filed 12 Jan 2024.